NASDAQ:PHAS • US7172241090
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for PHASEBIO PHARMACEUTICALS INC (PHAS).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2022-10-24 | Cowen & Co. | Downgrade | Outperform -> Market Perform |
| 2022-09-28 | William Blair | Downgrade | Outperform -> Market Perform |
| 2022-09-28 | Needham | Downgrade | Buy -> Hold |
| 2022-08-15 | Needham | Maintains | Buy |
| 2021-06-17 | Needham | Maintains | Buy |
| 2021-03-16 | Needham | Maintains | Buy |
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | ||
|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 2.36M 252.24% | 320K -86.44% | 10.831M 3,284.69% | 4.756M -56.09% | 3.135M -34.08% | 22.604M 621.02% | 55.403M 145.10% | 138.506M 150.00% | |
| EBITDA YoY % growth | -39.57M -102.61% | -84.35M -113.17% | -105.569M -25.16% | -89.168M 15.54% | -116.215M -30.33% | -124.415M -7.06% | -99.173M 20.29% | -80.634M 18.69% | |
| EBIT YoY % growth | -39.74M -102.34% | -84.86M -113.54% | -107.362M -26.52% | -84.925M 20.90% | -67.44M 20.59% | -69.857M -3.58% | -74.311M -6.37% | -80.629M -8.50% | |
| Operating Margin | -1,683.90% | -26,518.75% | -991.25% | -1,785.64% | -2,151.21% | -309.05% | -134.13% | -58.21% | |
| EPS YoY % growth | -1.42 71.19% | -3.39 -138.73% | -3.03 10.62% | -1.24 59.21% | -1.25 -1.19% | -0.93 25.92% | -1.02 -10.16% | -1.15 -12.36% |
All data in USD
| Q3 / 22 | Q4 / 22 | Q1 / 23 | Q2 / 23 | Q3 / 23 | Q4 / 23 | Q1 / 24 | Q2 / 24 | Q3 / 24 | Q4 / 24 | |
|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.38 42.20% | -0.32 64.19% | -0.13 42.35% | -0.09 73.00% | -0.09 75.94% | -0.09 71.52% | -0.31 -130.77% | -0.28 -200.00% | -0.26 -177.78% | -0.20 -122.22% |
| Revenue Q2Q % growth | -100.00% | 3.06M 1,836.71% | -100.00% | -100.00% | -100.00% | 6.442M | 10.721M | 14.045M | 20.711M | |
| EBITDA Q2Q % growth | -27.027M 1.32% | -17.731M 41.47% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -22.745M 20.41% | -19.238M 40.04% | -6.426M 64.75% | -4.08M 83.88% | -4.08M 82.06% | -4.08M 78.79% | N/A | N/A | N/A | N/A |
All data in USD
7 analysts have analysed PHAS and the average price target is 1.02 USD. This implies a price increase of 1355.06% is expected in the next year compared to the current price of 0.0701.
PHASEBIO PHARMACEUTICALS INC (PHAS) will report earnings on 2022-11-22, after the market close.
The consensus EPS estimate for the next earnings of PHASEBIO PHARMACEUTICALS INC (PHAS) is -0.38 USD and the consensus revenue estimate is 0 USD.
The number of analysts covering PHASEBIO PHARMACEUTICALS INC (PHAS) is 7.